The U.S. stock market is closed today, Thursday, December 25, 2025, in observance of the Christmas Day holiday, providing a pause after a robust, record-setting session on Christmas Eve. Both the New York Stock Exchange (NYSE) and Nasdaq will remain fully shut, with normal trading operations set to resume on Friday, December 26, 2025. This holiday closure follows a shortened trading day on Wednesday, December 24, when major indexes closed higher, with the S&P 500 and Dow Jones Industrial Average reaching ne ...

Today, Novo commands a market capitalization of roughly $230.4 billion, underscoring its scale and influence in the global pharma landscape. Even so, the stock hasn’t had a smooth ride in 2025. Multiple factors, including soft demand for its blockbuster drugs and intensifying competition in the weight-loss space, have eroded investor confidence.Best known for its blockbuster weight-loss drugs Ozempic and Wegovy, Novo Nordisk is one of the world’s most influential healthcare companies, with a deep-rooted foc ...

Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Telix Pharmaceuticals Limited due to allegations of violations of federal securities laws, specifically regarding misleading statements about the company's prostate cancer therapeutic candidates and supply chain quality [2][4]. Group 1: Legal Investigation and Class Action - The firm is encouraging investors who suffered losses in Telix between February 21, 2025, and August 28, 2025, to discuss their legal rights and options [1]. - A federal securities class action has been filed against Telix, with a deadline of January 9, 2026, for investors to seek the role of lead plaintiff [2]. - The lead plaintiff is defined as the investor with the largest financial interest in the relief sought, who will oversee the litigation on behalf of the class [7]. Group 2: Allegations Against Telix - The complaint alleges that Telix and its executives made false and misleading statements regarding the progress of prostate cancer therapeutic candidates and the quality of its supply chain [4]. - On July 22, 2025, Telix disclosed receiving a subpoena from the U.S. Securities and Exchange Commission, leading to a more than 13% drop in the price of its American Depositary Shares over two trading sessions [5]. - On August 28, 2025, Telix revealed it received a Complete Response Letter from the U.S. Food and Drug Administration for its product TLX250-CDx, which identified deficiencies in the Chemistry, Manufacturing, and Controls package, resulting in a more than 21% decline in share price over two trading sessions [6].

曾被奉为"止咳神药"的孟鲁司特，如今正因其精神类副作用而受到重新审视。近期，国家药监局修订了 该药的制剂说明书，明确警示其可能引发抑郁、自杀倾向等严重不良反应，并建议患者一旦出现相关症 状应立即停药就医。然而在现实中，孟鲁司特仍被广泛用于咳嗽、鼻炎等常见症状，存在一定的滥用现 象——仅原研药"顺尔宁"在单一平台的销量就已超过200万盒。 一边是部分患者家庭对其止咳效果的依赖，一边是日益受到关注的安全风险，孟鲁司特正从一种广泛使 用的止咳药，转向需要严格评估、谨慎使用的治疗选项。随着临床用药态度趋严，"用还是不用"的纠结 逐渐转向"用什么替代"。这场围绕孟鲁司特的争议，不仅折射出无数家庭面临的用药困境，也凸显出疗 效与安全性之间的权衡难题。 国家药监局升级警告 12月24日，在看到"问药师"创始人冀连梅发布的孟鲁司特用药提示，徐梅再一次陷入了焦虑。作为一名 重度过敏性鼻炎，伴有气道高反，且肺功能实验为阳性的患儿家长，徐梅对孟鲁司特制剂再熟悉不过： 不用控制不住咳嗽，就往喘的方向发展；用了，一段时间后鼻子与咳嗽好了，儿子开始出现眨眼睛，这 是公认抽动症的前兆。 "如果说之前美国FDA发出黑框警告时，我们出于对疗效 ...

U.S. financial markets are observing a full closure today, Thursday, December 25, 2025, in celebration of the Christmas holiday. Trading on both the New York Stock Exchange (NYSE) and Nasdaq is suspended for the entire day, with normal operations set to resume on Friday, December 26, 2025. This pause follows a shortened, yet record-setting, trading session on Christmas Eve, Wednesday, December 24, where major indexes continued their upward trajectory, fueling hopes of a "Santa Claus rally" to close out the ...

BofA raised the firm’s price target on Agios Pharmaceuticals (AGIO) to $34 from $32 and keeps a Buy rating on the shares following FDA approval for mitapivat to make it the only drug approved in both transfusion-dependent and non-transfusion-dependent alpha- or beta- thalassemia. The REMS and black box for hepatocellular injury were in line with the firm’s expectations and BofA doesn’t expect this to impact uptake, the analyst tells investors. Claim 70% Off TipRanks This Holiday Season Published first on ...

21世纪经济报道记者 韩利明 日前，国家药监局发布公告，明确要求孟鲁司特制剂（包含片剂、咀嚼片、颗粒和口溶膜四种剂型）在说明书中新增神经精神不良反 应的警示语，注明"其中包括个别严重反应如抑郁和自杀倾向等；若不停药，这些症状可能持续存在"。同时，在不良反应中增加"口 吃（结巴）"。 图片来源：国家药监局官网 公告要求，国内所有孟鲁司特药品的上市许可持有人，均应按上述要求修订说明书，并在2026年3月12日前报国家药监局药审中心或 省级药监部门备案。备案后9个月内，已出厂的药品说明书及标签要全部更换。 公开资料显示，孟鲁司特钠（编者注：孟鲁司特与孟鲁司特钠是同一种药物，规范的药物名称为孟鲁司特钠）由默沙东原研（商品 名：Singulair，顺尔宁），是一种强效选择性白三烯受体拮抗剂，适应症为2岁至14岁儿童哮喘的预防和长期治疗，包括预防白天和夜 间的哮喘症状，治疗对阿司匹林敏感的哮喘患者以及预防运动诱发的支气管收缩；减轻过敏性鼻炎引起的症状（2岁至14岁儿童的季 节性过敏性鼻炎和常年性过敏性鼻炎）。 随着默沙东专利到期，国内企业开展仿制。21世纪经济报道记者以"孟鲁司特"为关键词，在国家药监局官网共查询到62条 ...

Company Overview - Beximco Pharmaceuticals is a leading manufacturer and exporter of medicines based in Bangladesh, incorporated in 1976 [2] - The company initially imported products from Bayer, Germany, and Upjohn, USA, before starting its own manufacturing in 1980 under licensing arrangements [2] - Beximco Pharma launched its own formulation brands in 1983 and has been committed to providing access to contemporary medicines globally [2] Stock Performance - Beximco Pharmaceuticals' stock increased by 5.9%, with shares last traded at GBX 45 [1][4] - The stock crossed above its fifty-day moving average of GBX 41.80 during trading, reaching a high of GBX 45 [4] - The company has a market capitalization of £200.75 million and a price-to-earnings ratio of 0.03 [1] Financial Ratios - Beximco Pharmaceuticals has a debt-to-equity ratio of 12.47, indicating a high level of debt compared to equity [1] - The current ratio stands at 2.13, suggesting good short-term financial health, while the quick ratio is at 0.37 [1] - The fifty-day moving average price is GBX 41.80, and the two-hundred-day moving average price is GBX 42.40 [1]

Pfizer Inc. (NYSE:PFE) is one of the best high volume stocks to buy right now. On December 16, Bank of America analyst Jason Gerberry lowered the firm’s price target on Pfizer to $27 from $28 while keeping a Neutral rating on the shares. Pfizer’s 2026 guidance revealed a steeper erosion of its COVID-19 franchise than previously projected, leading the firm to trim its near-term financial forecasts. The focus has now shifted to the company’s obesity strategy; investors are awaiting trial results from the rec ...

【环球网财经综合报道】2025年A股IPO市场交出了一份亮眼的成绩单，同时也展现了鲜明的结构性变 化。最新统计数据显示，截至12月22日，年内A股发行上市家数共计106家，同比增长9.28%；募资总额 却高达1190.83亿元，同比激增91.23%。募资增速远超数量增速，直观反映出今年IPO市场"少而精"的特 征——超大型项目的密集落地成为募资规模跳涨的关键动力，这与A股从"规模扩张"向"质量优先"的转 型高度契合。 随着IPO市场的活跃，券商投行格局也迎来重塑。年内共有30家券商斩获A股IPO项目，保荐承销费用合 计60.03亿元，同比增长38.03%。值得注意的是，国泰君安与海通证券合并后的"国泰海通"效应显现， 以17家的保荐数量位居行业第一，超过中信证券。而在募资规模和承销费率方面，头部券商依然展现出 强大优势，中金公司以平均每单47.91亿元的募资额居首，华泰联合则以266.74亿元的实际募资规模排名 榜首。与此同时，大额项目也带来了承销费率的差异化，中金公司、华泰联合等大券商的平均承销费率 相对较低。 监管层面的变化同样值得关注。年内IPO终止审查企业共计107家，同比大幅减少75.34%。终止数 ...